Tamara Martos
7 Papers
35 Citations
Tamara Martos is an academic researcher. The author has contributed to research in topics: Breast cancer & Population. The author has an hindex of 2, co-authored 4 publications.
Chat about Author
Papers
Skeletal adverse effects with aromatase inhibitors in early breast cancer: evidence to date and clinical guidance.
Sonia Servitja,Tamara Martos,Maria Rodriguez Sanz,Natalia Garcia-Giralt,Daniel Prieto-Alhambra,Laia Garrigos,Xavier Nogués,Ignasi Tusquets +7 more
TL;DR: It is demonstrated that AIrA is genetically determined: single nucleotide polymorphisms located in genes encoding key factors for the metabolism of estrogens and vitamin D (CYP17A1, VDR, and CYP27B1) are associated with self-reported arthralgia during AI therapy.
Circulating Tumor Cells: Applications for Early Breast Cancer.
TL;DR: There is definitive evidence on the prognostic role of CTCs in early breast cancer (eBC) but its clinical utility in daily practice is still lacking and the combination of different methods to detect tumoral disease by liquid biopsy may provide new ways to personalize in an unprecedented manner the management of patients with eBC.
6
Abstract P4-01-28: PALBOSPAIN: OBSERVATIONAL ANALYSIS OF FIRST-LINE THERAPY WITH PALBOCICLIB IN PATIENTS WITH HR+/HER2- METASTATIC BREAST CANCER (MBC) IN REAL-LIFE CONDITIONS
Noelia Martínez-Jañez,M. Bellet Ezquerra,Fernando Henao,Luis Manso,Antonio Antón,Pilar Zamora,Serafin Morales Murillo,P. Tolosa,Raquel Andrés,Lourdes Calvo,Elena Galve,Rafael López,Francisco Ayala de la Peña,Sara López-Tarruella,Laia Boronat,Tamara Martos,Jose Ignacio Chacon,Isabel Alvarez,Juan De La Haba-Rodriguez,Fernando Moreno Antón +19 more
TL;DR: Martínez-Jáñez et al. as mentioned in this paper evaluated the efficacy and safety of palbociclib treatment under real-life conditions in patients with HR+/HER2-MBC.
2
Concordance between radiologic and pathologic complete response in patients with breast cancer treated with neoadjuvant chemotherapy.
Laia Garrigos,Maria Dolors Sabadell,Ana Rodríguez-Arana,Josep M. Corominas,Maria Martinez-Garcia,Iria Gonzalez,Tamara Martos,Joan Albanell,Ignacio Tusquets,Sonia Servitja +9 more
TL;DR: This retrospective study included patients with stage I-III who were treated with NAC at the authors' breast cancer unit between January 2006 and December 2012 and analyzed the correlation between radiological complete response and pathological complete response, globally and according to the different tumor immunophenotypes.
1
Bone turnover markers at 3 months of aromatase inhibitor therapy for prediction of 1-year bone mineral density loss: The B-ABLE cohort
Ignacio Tusquets,Sonia Servitja,D Prieto-Alhambra,Elisabet Torres,Laia Garrigos,Tamara Martos,Maria Rodriguez-Sanz,Adolf Diez-Perez,Joan Albanell,Xavi Nogues +9 more
TL;DR: Change in BTM levels (3-month minus baseline) was the main exposure and relative 1-year Lumbar Spine BMD loss (baseline minus 1- year over baseline) the main outcome of this study.
1